[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Bispecific antibody,Multiple myeloma,BCMA,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Jagannath<\/b><sup>1<\/sup>, J. Richter<sup>1<\/sup>, M. V. Dhodapkar<sup>2<\/sup>, J. E. Hoffman<sup>3<\/sup>, H. C. Lee<sup>4<\/sup>, A. Suvannasankha<sup>5<\/sup>, M. R. Shah<sup>6<\/sup>, S. Lentzsch<sup>7<\/sup>, J. A. Zonder<sup>8<\/sup>, R. Baz<sup>9<\/sup>, J. J. Maly<sup>10<\/sup>, S. Namburi<sup>11<\/sup>, K. L. Wu<sup>12<\/sup>, M. Pianko<sup>13<\/sup>, R. Silbermann<sup>14<\/sup>, C.-K. Min<sup>15<\/sup>, M.-C. Vekemans<sup>16<\/sup>, M. Munder<sup>17<\/sup>, J. M. Byun<sup>18<\/sup>, J. M. Lopez<sup>19<\/sup>, M. DeVeaux<sup>20<\/sup>, D. Chokshi<sup>20<\/sup>, A. Boyapati<sup>20<\/sup>, A. Hazra<sup>20<\/sup>, K. R. Lorenc<sup>20<\/sup>, G. S. Kroog<sup>20<\/sup>, Y. Houvras<sup>20<\/sup>, N. Bumma<sup>21<\/sup>; <br\/><sup>1<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2<\/sup>Emory University School of Medicine, Atlanta, GA, <sup>3<\/sup>University of Miami Health System, Miami, FL, <sup>4<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>5<\/sup>Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, <sup>6<\/sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, <sup>7<\/sup>Columbia University Medical Center, New York, NY, <sup>8<\/sup>Karmanos Cancer Institute, Detroit, MI, <sup>9<\/sup>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, <sup>10<\/sup>Norton Cancer Institute, Louisville, KY, <sup>11<\/sup>Swedish Cancer Institute, Seattle, WA, <sup>12<\/sup>Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium, <sup>13<\/sup>University of Michigan Health, Rogel Cancer Center, Ann Arbor, MI, <sup>14<\/sup>Knight Cancer Institute, Oregon Health & Science University, Portland, OR, <sup>15<\/sup>Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of, <sup>16<\/sup>Department of Internal Medicine, Universit√© Catholique de Louvain (UCLouvain), Brussels, Belgium, <sup>17<\/sup>Third Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany, <sup>18<\/sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>19<\/sup>Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO, Madrid, Spain, <sup>20<\/sup>Regeneron Pharmaceuticals, Inc., Tarrytown, NY, <sup>21<\/sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH","CSlideId":"","ControlKey":"2d9ce9d7-9ece-4d21-886f-513a29c440c9","ControlNumber":"10358","DisclosureBlock":"<b>&nbsp;S. Jagannath, <\/b> <br><b>Mount Sinai Hospital<\/b> Employment. <br><b>Bristol Myers Squibb<\/b> Other, Consultancy. <br><b>Janssen<\/b> Other, Consultancy. <br><b>Sanofi<\/b> Other, Consultancy. <br><b>Caribou Biosciences<\/b> Other, Consultancy. <br><b>Takeda<\/b> Other, Consultancy. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Other, Consultancy. <br><b>DMC<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>J. Richter, <\/b> <br><b>Abbvie<\/b> Other, Consultancy. <br><b>Adaptive Biotechnologies<\/b> Membership on an entity's Board of Directors or advisory committees. <br><b>AstraZeneca<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Bristol Myers Squibb<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Celgene<\/b> Other, Consultancy, Membership on an entity's Board of Directors or advisory committees and Speakers Bureau. <br><b>Genentech<\/b> Other, Consultancy. <br><b>Janssen<\/b> Other, Membership on an entity's Board of Directors or advisory committees and Speakers Bureau. <br><b>Karyopharm<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Pfizer<\/b> Other, Consultancy. <br><b>Sanofi<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Takeda<\/b> Other, Consultancy and Membership on an entity's Board of Directors or advisory committees. <br><b>M. V. Dhodapkar, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Lava Therapeutics<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Sanofi<\/b> Other, Membership on an entity's Board of Directors or advisory committees.<br><b>J. E. Hoffman, <\/b> None.&nbsp;<br><b>H. C. Lee, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consultancy. <br><b>Genentech<\/b> Other, Consultancy. <br><b>GlaxoSmithKline<\/b> Grant\/Contract, Other, Consultancy. <br><b>Sanofi<\/b> Other, Consultancy. <br><b>Pfizer<\/b> Other, Consultancy. <br><b>Monte Rosa Therapeutics<\/b> Other, Consultancy. <br><b>Takeda<\/b> Grant\/Contract, Other, Consultancy. <br><b>Allogene Therapeutics<\/b> Other, Consultancy. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Grant\/Contract, Consultancy. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract, Consultancy. <br><b>Celgene<\/b> Other, Consultancy.<br><b>A. Suvannasankha, <\/b> None.&nbsp;<br><b>M. R. Shah, <\/b> <br><b>Janssen<\/b> Other, Consultancy. <br><b>Bristol Myers Squibb<\/b> Other, Consultancy. <br><b>S. Lentzsch, <\/b> <br><b>Adaptive Biotechnologies<\/b> Other, Consultancy and Membership on an entity's Board of Directors or advisory committees. <br><b>Alexion Pharmaceuticals<\/b> Consultancy and Membership on an entity's Board of Directors or advisory committees. <br><b>Bristol Myers Squibb<\/b> Membership on an entity's Board of Directors or advisory committees. <br><b>Caelum Biosciences<\/b> Membership on an entity's Board of Directors or advisory committees and Patents & Royalties: January 1, 2041. <br><b>Celgene<\/b> Grant\/Contract. <br><b>Clinical Care Options<\/b> Other, Honoraria. <br><b>Janssen<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Karyopharm Therapeutics<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Oncopeptide<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Pfizer<\/b> Other, Consultancy. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Other, Honoraria. <br><b>Sanofi<\/b> Grant\/Contract. <br><b>Takeda<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>J. A. Zonder, <\/b> <br><b>Janssen<\/b> Other, Consultancy. <br><b>Prothena<\/b> Other, Consultancy. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Other, Consultancy. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Celgene<\/b> Grant\/Contract. <br><b>Takeda<\/b> Other, Consultancy which has ended within the\u000d\u000apast 24 months. <br><b>Telios<\/b> Consultancy which has ended within the\u000d\u000apast 24 months. <br><b>R. Baz, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Membership on an entity's Board of directors or advisory committees. <br><b>AbbVie<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract, Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Karyopharm<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>GlaxoSmithKline<\/b> Other, Honoraria. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Grant\/Contract. <br><b>HIKMA Cancer Network<\/b> Other, Honoraria. <br><b>Curio Science<\/b> Other, Honoraria. <br><b>AHOMPR<\/b> Other, Honoraria. <br><b>ASH<\/b> Other, Honoraria.<br><b>J. J. Maly, <\/b> None.&nbsp;<br><b>S. Namburi, <\/b> <br><b>Janssen<\/b> Other, Honoraria. <br><b>Genentech<\/b> Other, Honoraria. <br><b>Bristol Myers Squibb<\/b> Other, Honoraria.<br><b>K. L. Wu, <\/b> None.&nbsp;<br><b>M. Pianko, <\/b> <br><b>Pfizer<\/b> Grant\/Contract, Other, Consultancy. <br><b>Janssen<\/b> Grant\/Contract, Other, Consultancy, Honoraria. <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract, Other, Honoraria. <br><b>Nektar<\/b> Grant\/Contract. <br><b>Abbvie<\/b> Grant\/Contract.<br><b>R. Silbermann, <\/b> None..<br><b>C. Min, <\/b> None..<br><b>M. Vekemans, <\/b> None.&nbsp;<br><b>M. Munder, <\/b> <br><b>Janssen<\/b> Other, Consultancy and Honoraria. <br><b>Bristol Myers Squibb<\/b> Other, Consultancy and Honoraria. <br><b>Sanofi<\/b> Other, Consultancy and Honoraria. <br><b>GlaxoSmithKline<\/b> Other, Consultancy and Honoraria. <br><b>Takeda<\/b> Other, Honoraria. <br><b>Incyte<\/b> Grant\/Contract.<br><b>J. M. Byun, <\/b> None.&nbsp;<br><b>J. M. Lopez, <\/b> <br><b>Janssen<\/b> Grant\/Contract, Other, Consultancy and Speakers Bureau. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consultancy and Speakers Bureau. <br><b>Sanofi<\/b> Other, Consultancy and Speakers Bureau. <br><b>GlaxoSmithKline<\/b> Other, Consultancy and Speakers Bureau. <br><b>Novartis<\/b> Other, Consultancy and Speakers Bureau. <br><b>Menarini<\/b> Other, Consultancy and Speakers Bureau. <br><b>Incity<\/b> Other, Consultancy and Speakers Bureau. <br><b>Roche<\/b> Other, Consultancy and Speakers Bureau. <br><b>Gilead<\/b> Other, Consultancy and Speakers Bureau. <br><b>M. DeVeaux, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock Option. <br><b>D. Chokshi, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock Option. <br><b>A. Boyapati, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment. <br><b>A. Hazra, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock Option. <br><b>K. R. Lorenc, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock Option. <br><b>G. S. Kroog, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock Option. <br><b>Y. Houvras, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment.<br><b>N. Bumma, <\/b> None.","End":"4\/7\/2024 1:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11419","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT001","PresenterBiography":null,"PresenterDisplayName":"Sundar Jagannath, MD","PresenterKey":"c49cc5ad-f2c2-48f1-ba5d-348ec2e6c0bf","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT001. Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 1:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"6f11eaac-7a75-483c-a284-b8ae00aeec65","ControlNumber":"12128","DisclosureBlock":"","End":"4\/7\/2024 1:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11827","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 1:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Phase I,CAR T cells,CD70,Renal cell carcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. K. Pal<\/b><sup>1<\/sup>, B. Tran<sup>2<\/sup>, J. B. Haanen<sup>3<\/sup>, M. Hurwitz<sup>4<\/sup>, A. Sacher<sup>5<\/sup>, N. Agarwal<sup>6<\/sup>, N. Tannir<sup>7<\/sup>, E. Budde<sup>1<\/sup>, S. Harrison<sup>2<\/sup>, S. Klobuch<sup>3<\/sup>, S. S. Patel<sup>6<\/sup>, M.-L. Dequeant<sup>8<\/sup>, Q. He<sup>8<\/sup>, A. Keegan<sup>8<\/sup>, H. Dar<sup>8<\/sup>, A. Ma<sup>8<\/sup>, P. Morrow<sup>8<\/sup>, S. A. Srour<sup>7<\/sup>; <br\/><sup>1<\/sup>City of Hope Comprehensive Cancer Center, Duarte, CA, <sup>2<\/sup>Peter MacCallum Cancer Centre, Melbourne, Australia, <sup>3<\/sup>Netherlands Cancer Institute, Amsterdam, Netherlands, <sup>4<\/sup>Yale School of Medicine, New Haven, CT, <sup>5<\/sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, <sup>6<\/sup>Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City, UT, <sup>7<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>8<\/sup>CRISPR Therapeutics, Boston, MA","CSlideId":"","ControlKey":"bee1b52d-28e3-4e0c-a5fa-e7acd9e7a58e","ControlNumber":"10822","DisclosureBlock":"<b>&nbsp;S. K. Pal, <\/b> <br><b>CRISPR Therapeutics<\/b> Travel. <br><b>Ipsen<\/b> Travel. <br><b>Exelixis<\/b> Travel.<br><b>B. Tran, <\/b> None..<br><b>J. B. Haanen, <\/b> None..<br><b>M. Hurwitz, <\/b> None..<br><b>A. Sacher, <\/b> None..<br><b>N. Agarwal, <\/b> None..<br><b>N. Tannir, <\/b> None..<br><b>E. Budde, <\/b> None..<br><b>S. Harrison, <\/b> None..<br><b>S. Klobuch, <\/b> None..<br><b>S. S. Patel, <\/b> None.&nbsp;<br><b>M. Dequeant, <\/b> <br><b>CRISPR Therapeutics<\/b> Employment. <br><b>Q. He, <\/b> <br><b>CRISPR Therapeutics<\/b> Employment. <br><b>A. Keegan, <\/b> <br><b>CRISPR Therapeutics<\/b> Employment. <br><b>H. Dar, <\/b> <br><b>CRISPR Therapeutics<\/b> Employment. <br><b>A. Ma, <\/b> <br><b>CRISPR Therpeutics<\/b> Employment. <br><b>P. Morrow, <\/b> <br><b>CRISPR Therapeutics<\/b> Employment.<br><b>S. A. Srour, <\/b> None.","End":"4\/7\/2024 1:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11420","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT002","PresenterBiography":null,"PresenterDisplayName":"Sumanta Pal, MD","PresenterKey":"5a67e41f-e94b-4be0-8925-57f247665aba","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT002. CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"4db11160-31e0-4a0a-b464-379f0e92170c","ControlNumber":"12129","DisclosureBlock":"","End":"4\/7\/2024 2:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11828","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 1:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Oncolytic virus,Immunotherapy,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. R. Migden<\/b><sup>1<\/sup>, W. Chai-Ho<sup>2<\/sup>, G. A. Daniels<sup>3<\/sup>, T. Medina<sup>4<\/sup>, T. M. Wise-Draper<sup>5<\/sup>, M. Kheterpal<sup>6<\/sup>, J. C. Tang<sup>7<\/sup>, S. F. Ibrahim<sup>8<\/sup>, D. Bolotin<sup>9<\/sup>, C. Verschraegen<sup>10<\/sup>, N. C. Zeitouni<sup>11<\/sup>, K. K. Tsai<sup>12<\/sup>, L. Donthireddy<sup>13<\/sup>, P. K. Bommareddy<sup>13<\/sup>, J. W. Hou<sup>13<\/sup>, W. Hong<sup>13<\/sup>, D. Davar<sup>14<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>UCLA David Geffen School of Medicine, Los Angeles, CA, <sup>3<\/sup>Moores Cancer Center, University of California San Diego, La Jolla, CA, <sup>4<\/sup>University of Colorado Cancer Center, Aurora, CO, <sup>5<\/sup>Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, <sup>6<\/sup>Department of Dermatology, Duke University Medical Center, Durham, NC, <sup>7<\/sup>University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, <sup>8<\/sup>Rochester Dermatologic Surgery, Victor, NY, <sup>9<\/sup>University of Chicago, Department of Medicine, Section of Dermatology, Chicago, IL, <sup>10<\/sup>Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, <sup>11<\/sup>University of Arizona College of Medicine and US Dermatology Partners, Phoenix, AZ, <sup>12<\/sup>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, <sup>13<\/sup>Replimune, Inc., Woburn, MA, <sup>14<\/sup>UPMC Hillman Cancer Center, Pittsburgh, PA","CSlideId":"","ControlKey":"5544d328-515f-4b24-807c-9d0012227420","ControlNumber":"9629","DisclosureBlock":"<b>&nbsp;M. R. Migden, <\/b> <br><b>Replimune, Inc.<\/b> Other, Paid advisor, research funding. <br><b>Regeneron<\/b> Other, Paid advisor, research funding. <br><b>Feldan<\/b> Other, Paid advisor. <br><b>Sanofi<\/b> Paid advisor, research funding. <br><b>Stamford Pharmaceuticals<\/b> Other, Paid advisor. <br><b>Sun Pharmaceutical Industries Ltd<\/b> Paid advisor. <br><b>Senhwa<\/b> Research funding. <br><b>W. Chai-Ho, <\/b> <br><b>Servier<\/b> Other, Advisory Board.<br><b>G. A. Daniels, <\/b> None.&nbsp;<br><b>T. Medina, <\/b> <br><b>University of Colorado Cancer Center<\/b> Other, Institutional funding. <br><b>T. M. Wise-Draper, <\/b> <br><b>Exicure<\/b> Other, Consulting\/Advisory role. <br><b>Merck<\/b> Other, Consulting\/advisory role and research funding. <br><b>Caris Life Science<\/b> Travel, Other, Consulting\/advisory role and research funding. <br><b>High Enroll<\/b> Stock. <br><b>AstraZeneca\/MedImmune<\/b> Other, Research funding. <br><b>Bristol-Myers Squibb<\/b> Other, Research funding. <br><b>GlaxoSmithKline<\/b> Other, Research funding. <br><b>Janssen Oncology<\/b> Other, Research funding. <br><b>M. Kheterpal, <\/b> <br><b>Replimune, Inc.<\/b> Other, Data Safety Monitoring Board, receipt of drug for trial.<br><b>J. C. Tang, <\/b> None.&nbsp;<br><b>S. F. Ibrahim, <\/b> <br><b>Replimune, Inc.<\/b> Other, Study funding, Data Safety Monitoring Board. <br><b>D. Bolotin, <\/b> <br><b>Replimune, Inc.<\/b> Other, Sponsored trial site. <br><b>Pelle Pharma<\/b> Other, Sponsored clinical trial. <br><b>Chicago Dermatologic Society Research Grant<\/b> Other, Institutional funding of a translational research project. <br><b>Illinois Dermatologic Society, Chicago Dermatologic Society, Hyde Park School of Dance, Association of Academic Cosmetic Dermatology<\/b> Board of Directors. <br><b>JAAD, Dermatologic Surgery, Archives of Dermatologic Research journals<\/b> Editorial board.<br><b>C. Verschraegen, <\/b> None.&nbsp;<br><b>N. C. Zeitouni, <\/b> <br><b>Replimune, Inc.<\/b> Other, Inv. <br><b>SunPharma<\/b> Other, Inv\/consultant. <br><b>Biofrontera<\/b> Other, Inv, consultant. <br><b>Castle Biosciences<\/b> Other, Inv and speaker program. <br><b>Dermasensor<\/b> Other, Inv. <br><b>Regeneron<\/b> Other, Inv and speaker program. <br><b>K. K. Tsai, <\/b> <br><b>Replimune, Inc.<\/b> Other, Institutional research funding. <br><b>Genentech<\/b> Other, Institutional research funding. <br><b>Pfizer<\/b> Other, Institutional research funding. <br><b>Oncosec<\/b> Other, Institutional research funding. <br><b>ABM Therapeutics<\/b> Other, Institutional research funding. <br><b>BMS<\/b> Other, Institutional research funding and advisory board (consulting fees). <br><b>Regeneron<\/b> Other, Institutional research funding and advisory board (consulting fees). <br><b>L. Donthireddy, <\/b> <br><b>Replimune, Inc.<\/b> Employment. <br><b>P. K. Bommareddy, <\/b> <br><b>Replimune, Inc.<\/b> Employment, Stock. <br><b>J. W. Hou, <\/b> <br><b>Replimune, Inc.<\/b> Employment. <br><b>W. Hong, <\/b> <br><b>Replimune<\/b> Employment. <br><b>D. Davar, <\/b> <br><b>Arcus<\/b> Grant\/Contract. <br><b>CellSight Technologies<\/b> Grant\/Contract. <br><b>Immunocore<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Regeneron Pharmaceuticals Inc.<\/b> Grant\/Contract. <br><b>Tesaro\/GSK<\/b> Grant\/Contract. <br><b>ACM Bio<\/b> Other, Consulting fees. <br><b>Ascendis Pharma<\/b> Other, Consulting fees. <br><b>Gerson Lehrman Group<\/b> Other, Consulting fees. <br><b>Xilio Therapeutics<\/b> Other, Consulting fees. <br><b>Clinical Care Options<\/b> Other, Honoraria. <br><b>Medical Learning Group<\/b> Other, Honoraria.","End":"4\/7\/2024 2:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11421","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT003","PresenterBiography":null,"PresenterDisplayName":"Michael Migden, MD","PresenterKey":"00a406e5-0fc3-4771-96e2-ae637330b771","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT003. Initial results from an open-label phase 1b\/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 2:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Initial results from an open-label phase 1b\/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"c77f5468-487c-48da-b720-b907839bc98e","ControlNumber":"12130","DisclosureBlock":"","End":"4\/7\/2024 2:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11829","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 2:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Squamous cell carcinoma,HSV,Immunotherapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Curiel-Lewandrowski<\/b><sup>1<\/sup>, D. B. Stratton<sup>1<\/sup>, A. C. Adams<sup>2<\/sup>, H. Cui<sup>1<\/sup>, D. Roe<sup>1<\/sup>, S. Sundararajan<sup>3<\/sup>; <br\/><sup>1<\/sup>University of Arizona, Tucson, AZ, <sup>2<\/sup>University of Arizona, Phoenix, AZ, <sup>3<\/sup>Texas Oncology, Katy, TX","CSlideId":"","ControlKey":"82790692-6b30-4681-98f1-29d62ff57cf9","ControlNumber":"10512","DisclosureBlock":"<b>&nbsp;C. Curiel-Lewandrowski, <\/b> <br><b>Amgen<\/b> Grant\/Contract.<br><b>D. B. Stratton, <\/b> None..<br><b>A. C. Adams, <\/b> None..<br><b>H. Cui, <\/b> None..<br><b>D. Roe, <\/b> None..<br><b>S. Sundararajan, <\/b> None.","End":"4\/7\/2024 2:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11422","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT004","PresenterBiography":null,"PresenterDisplayName":"Clara Curiel","PresenterKey":"bc07803a-7ed9-481d-8511-a4be46c77a63","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT004. A single arm phase 2 study of TVEC in patients with invasive cutaneous SCC: A novel therapeutic approach for low risk tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 2:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A single arm phase 2 study of TVEC in patients with invasive cutaneous SCC: A novel therapeutic approach for low risk tumors","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"b110e2c7-18fa-495c-95a4-d32aba40a2ee","ControlNumber":"12131","DisclosureBlock":"","End":"4\/7\/2024 3:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11830","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:00PM","SessionId":"659","SessionOnDemand":"False","SessionTitle":"Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies","ShowChatLink":"false","Start":"4\/7\/2024 2:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]